The Annals Summaries of the Latest Medical Research!
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     


The Annals of Pharmacotherapy: Vol. 36, No. 3, pp. 489-503. DOI 10.1345/aph.1A204
© 2002 Harvey Whitney Books Company.
This Article
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dager, W.
Right arrow Articles by White, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dager, W.
Right arrow Articles by White, R.


Research Articles

Treatment of heparin-induced thrombocytopenia

WE Dager and RH White

OBJECTIVE: To describe heparin-induced thrombocytopenia (HIT or HIT-2), an immune-mediated adverse reaction to heparin or low-molecular-weight heparin. Available treatment options and considerations in developing a therapy approach are discussed. DATA SOURCES: A search of the National Library of Medicine (1992-June 2001) was done to identify pertinent literature. Additional references were reviewed from selected articles. STUDY SELECTION: Articles related to laboratory recognition and treatment options of HIT, including the use of agents in selected clinical conditions, were reviewed and included. CONCLUSIONS: HIT is a rare but potentially severe adverse reaction to heparin that was, until recently, poorly understood and had limited treatment options. Recent advances describing the recognition and clinical manifestations of immune-mediated HIT, including recently available antithrombotic treatment options, have dramatically changed outcomes for patients having this syndrome.


This article has been cited by other articles:


Home page
The Annals of PharmacotherapyHome page
E. A Nutescu, A. K Wittkowsky, P. P Dobesh, D. W Hawkins, and W. E Dager
Choosing the Appropriate Antithrombotic Agent for the Prevention and Treatment of VTE: A Case-Based Approach
Ann. Pharmacother., September 1, 2006; 40(9): 1558 - 1570.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
S. E. Hallman, L. Hebbar, J. Robison, and W. E. Uber
The Use of Argatroban for Carotid Endarterectomy in Heparin-Induced Thrombocytopenia
Anesth. Analg., April 1, 2005; 100(4): 946 - 948.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
J. L Stephens, J. M Koerber, J. C Mattson, and M. A Smythe
Effect of Lepirudin on the International Normalized Ratio
Ann. Pharmacother., January 1, 2005; 39(1): 28 - 31.
[Abstract] [Full Text] [PDF]


Home page
Postgrad. Med. J.Home page
A complication of hip surgery
Postgrad. Med. J., May 1, 2003; 79(931): 301 - 301.
[Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
T. N Nguyen, P. Gal, J L. Ransom, and R. Carlos
Lepirudin Use in a Neonate with Heparin-Induced Thrombocytopenia
Ann. Pharmacother., February 1, 2003; 37(2): 229 - 233.
[Abstract] [Full Text] [PDF]




homecopy help contact us subscription past issues search current issue
Copyright © 2002 by Harvey Whitney Books Company.